BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37543655)

  • 1. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.
    Hoshitsuki K; Zhou Y; Miller AM; Choi JK; Swanson HD; Bhakta NH; Jeha S; Karol SE; Ribeiro RC; Rubnitz JE; Mullighan CG; Cheng C; Yang JJ; Relling MV; Pui CH; Inaba H
    Leukemia; 2023 Sep; 37(9):1782-1791. PubMed ID: 37543655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
    Vrooman LM; Blonquist TM; Stevenson KE; Supko JG; Hunt SK; Cronholm SM; Koch V; Kay-Green S; Athale UH; Clavell LA; Cole PD; Harris MH; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Place AE; Schorin MA; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2021 Nov; 39(31):3496-3505. PubMed ID: 34228505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
    Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Geyer MB; Ritchie EK; Rao AV; Vemuri S; Flynn J; Hsu M; Devlin SM; Roshal M; Gao Q; Shukla M; Salcedo JM; Maslak P; Tallman MS; Douer D; Park JH
    Haematologica; 2021 Aug; 106(8):2086-2094. PubMed ID: 33054114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Yampolsky H; Cohen LJ; Watkins K; Levine AM; Periclou AP; Avramis VI
    Blood; 2007 Apr; 109(7):2744-50. PubMed ID: 17132721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
    Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
    Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication.
    Losasso M; Bostrom B; Messinger Y
    F1000Res; 2019; 8():1007. PubMed ID: 32089823
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
    Ebeid EN; Kamel MM; Ali BA
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
    Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
    J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegaspargase-induced pancreatitis.
    Alvarez OA; Zimmerman G
    Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
    Rodriguez V; Kairalla J; Salzer WL; Raetz EA; Loh ML; Carroll AJ; Heerema NA; Wood BL; Borowitz MJ; Burke MJ; Asselin BL; Devidas M; Winick NJ; Carroll WL; Hunger SP; Dreyer ZE
    J Pediatr Hematol Oncol; 2016 Aug; 38(6):409-17. PubMed ID: 27299599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
    MacDonald T; Kulkarni K; Bernstein M; Fernandez CV
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):341-4. PubMed ID: 26925715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
    Heo YA; Syed YY; Keam SJ
    Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
    Lau KM; Saunders IM; Goodman A
    J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of asparaginase activity levels following treatment with pegaspargase.
    Bleyer A; Asselin BL; Koontz SE; Hunger SP
    Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.